Cowen Downgrades Alimera Sciences (ALIM) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Alimera Sciences Announces First Quarter 2016 Financial Results
May 4, 2016 4:23 PM EDTFirst quarter revenue improved 49% compared to first quarter 2015 due to increasing ILUVIEN® sales in the U.S.Record benefit investigations in the first quarter indicate increasing physician demandOver 5,000 eyes treated with ILUVIEN® in four primary marketsAlimera to host conference call on May 5, 2016 at 10:00 AM ET
ATLANTA, May 04, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of... More
